Iovance Biotherapeutics Inc (IOVA)

[surfkast]

The therapy, called lifileucel and commercially known as Amtagvi, is marketed by San Carlos-based Iovance Biotherapeutics.

Clinical trials of lifileucel for metastatic melanoma that worsened while on standard treatment found that about 30% of 153 patients who received the therapy had their tumors shrink or disappear. Of those, 40% experienced no progression of their cancers for at least 18 months after the one-time infusion.